To enable a universally applicable gene therapy for DBA, we sought to modify engraftable LT-HSCs with a GATA1 transgene that is only expressed after erythroid lineage commitment, and that mimics the temporal expression pattern of endogenous GATA117 (Fig. 1A). This evidence concerns the gene GATA1 and Diamond-Blackfan anemia.